X-linked Hypophosphatemic Rickets/Osteomalacia Clinical Trial
Official title:
A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia and a Postmarketing Study of KRN23 Switched From the Phase 3 Trial
Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 administered subcutaneously once every 2 weeks in children with X-linked hypophosphatemic rickets/osteomalacia(XLH). After switching to the post-marketing study: To evaluate the safety and efficacy of KRN23, which is switched from the investigational product to the post-marketing study drug, at the approved dose and dosing regimen in subjects who continue treatment
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02181764 -
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
|
Phase 1 |